Table 2 List of some approved vaccines
Vaccine | Vaccine platform | Effectivity |
|---|---|---|
SinoVac vaccine (Coronavac) | Inactivated virus | 50% effective against P.1 in Brazil [24]; 96.8% efficacy against COVID-19 in Indonesia [51] |
Covaxin BBV152 (Bharat Biotech-Indian Council of Medical Research) | Inactivated virus | 81% interim efficacy in preventing COVID-19 (SARS-CoV-2 original variant) [52]; 78% effective against the double mutant variant [24]; third dose neutralizes antibody responses against β and Omicron variants (14.70 and 18.53 fold, respectively) [53] |
ChAdOx1-S-/AZD1222 (AstraZeneca/University of Oxford) | Viral vector (non-replicating) | 70.4% efficacy against α variant [54]. 60–70% efficacy against ancestor and B.1.1.7 variants in UK, Brazil and South Africa, but did not protect against B.1.351 variant [55] |
Ad26.COV2.S (Janssen Pharmaceutical) | Viral vector (non-replicating) | Protects over 80% of Syrian hamster and non-human primate SARS-CoV-2 infection models [56]; but 59% effective against COVID-19 hospitalization [57] |
SARS-CoV-2 rS (Novavax) | Protein subunit | 95.6% effective against SARS-CoV-2 wild type; 85.6% and 60% effective against α and β variants [58] |
CVnCoV vaccine (Curevac AG) | Nucleic acid vaccine (RNA based) | Low efficacy [59], up to 47% efficacy against SARS-CoV-2 [60] |
mRNA-1273 (Moderna-NIAID) | Nucleic acid vaccine (RNA based) | 94% efficacy in preventing COVID-19 illness [61] |
BNT162b2 (3LNP-mRNAs) (Pfizer/BioNTech) | Nucleic acid vaccine (RNA based) |